Trastuzumab deruxtecan is indicated for the treatment of unresectable or metastatic HER2-positive breast cancer in adult patients who have previously received one or more anti-HER2-based regimens; it is also approved for the treatment of HER2-low metastatic breast cancer. As the first tumor-agnostic antibody-drug conjugate (ADC), it is approved for HER2-positive solid tumors regardless of tumor origin. Additionally, it has received Breakthrough Therapy Designation (BTD) from the U.S. FDA for the treatment of unresectable or metastatic hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+/ISH−) or HER2-ultra-low (IHC >0<1+) breast cancer in patients who have progressed after two lines of endocrine therapy for metastatic disease or within 6 months of first-line endocrine therapy combined with a CDK4/6 inhibitor, or within 24 months after adjuvant endocrine therapy. Trastuzumab deruxtecan demonstrates antitumor activity in HER2-positive breast cancer and gastric cancer, and exhibits a bystander killing effect against neighboring HER2-negative tumor cells.